Geron (NASDAQ:GERN) Price Target Lowered to $3.50 at B. Riley

Geron (NASDAQ:GERN - Free Report) had its target price trimmed by B. Riley from $5.50 to $3.50 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company's stock. B. Riley also issued estimates for Geron's FY2025 earnings at ($0.08) EPS, FY2026 earnings at $0.12 EPS and FY2027 earnings at $0.28 EPS.

A number of other research analysts also recently weighed in on the company. Needham & Company LLC upped their target price on Geron from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 13th. Barclays upgraded Geron to a "strong-buy" rating in a report on Friday, November 29th. Finally, HC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Geron in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.91.

Geron Stock Down 2.1 %

Shares of GERN stock traded down $0.06 during midday trading on Tuesday, reaching $2.58. 8,941,561 shares of the stock were exchanged, compared to its average volume of 11,788,855. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The company's 50 day moving average is $3.13 and its two-hundred day moving average is $3.88. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.56 billion, a PE ratio of -8.05 and a beta of 0.53.

Hedge Funds Weigh In On Geron

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GERN. RTW Investments LP bought a new position in Geron in the 3rd quarter valued at approximately $200,268,000. Holocene Advisors LP bought a new position in Geron in the 3rd quarter valued at approximately $82,498,000. Janus Henderson Group PLC lifted its position in Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company's stock valued at $102,193,000 after acquiring an additional 13,163,889 shares in the last quarter. Vestal Point Capital LP lifted its position in Geron by 947.6% in the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company's stock valued at $38,940,000 after acquiring an additional 9,950,000 shares in the last quarter. Finally, Braidwell LP bought a new position in Geron in the 4th quarter valued at approximately $24,802,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.